Development in Cell & Gene Therapy to Treat Rare and Difficult Indications
What are the Cell and Gene Therapies of the Future?
Development in Neurology and Ophthalmology
Development in Stem Cell Therapeutics and Regenerative Medicine
Development in Cell Therapy for Solid Tumours
Development for Non-Oncology Indications
Development in Allogeneic Cellular Therapies

Development in Cell & Gene Therapy to Treat Rare and Difficult Indications

28 Jan 2022
Charles River

09:00 Chairperson’s Opening
Holly May, Chief Commercial Officer, AVROBIO

09:05 Treating Underserved Patient Populations: Overcoming Development and Supply Challenges for Orphan Populations

  • Evaluating novel gene therapy treatment modalities for rare disease
  • Overcoming the manufacturing bottleneck and streamlining the regulatory path
  • Developing a business model with rare disease in mind

John Maslowski, Chief Commercial Officer, Forge Biologics

09:20 Integrated and Aligned End-to-End Vector and Cell Production: Charles River C&GT 360° Portfolio

  • Charles River is building a comprehensive portfolio of integrated services from early discovery to clinical and commercial C&GT manufacturing
  • We will present on our integrated and aligned C&GT development and manufacturing services, profiling key strategic partnerships that augment the service offering

Daniel Smith, Global Cell & Gene Therapy Portfolio, Strategic Alliances, Corporate Development & Strategy, Charles River Laboratories

09:35 CAAR-T Therapy for the Potential Treatment and Cure of B Cell Mediated Autoimmune Disease

  • Prioritizing indications which show promise for CAR-T-based approaches, and sharing rationale in preclinical development
  • Sharing progress in pre-clinical development of pipeline programs

Samik Basu, Vice President, Preclinical and Translational Science, Cabaletta Bio

09:50 Treating Cancer and Covid – Use of Banked Allogeneic Gamma-Delta T Cells in Oncology and Severe Viral Infection

  • Clinical data generated using allogenic gamma-delta cells for treatment of cancer was used to enable regulatory submission for covid treatment
  • Transition from a fresh allogenic to frozen product facilitated true ‘off-the-shelf’ availability
  • Overview of ongoing phase 1b/2a clinical to treat patients with covid-19

Michael Leek, Executive Chairman, TC Biopharm

10:05 Speaker Q&A and Panel Discussion


Holly May
Chief Commercial Officer
John Maslowski
Chief Commercial Officer
Forge Biologics
Daniel C. Smith
Executive Director, Global Cell & Gene Therapy Portfolio
Charles River
Samik Basu
Chief Scientific Officer
Cabaletta Bio
Michael Leek
Executive Chairman
TC BioPharm